Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $55.00 at Robert W. Baird

Apellis Pharmaceuticals (NASDAQ:APLS) had its price objective cut by Robert W. Baird from $92.00 to $55.00 in a report released on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s price objective suggests a potential upside of 91.37% from the company’s current price.

Other research analysts also recently issued research reports about the company. Mizuho decreased their price objective on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a report on Thursday, October 24th. Wedbush lifted their target price on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, August 9th. Bank of America lowered their price objective on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a research report on Wednesday. Evercore ISI raised Apellis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 31st. Finally, UBS Group cut their price target on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a report on Friday, August 9th. Six analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $51.06.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ APLS traded down $0.09 during trading hours on Thursday, reaching $28.74. 1,124,915 shares of the stock traded hands, compared to its average volume of 1,777,589. The company has a market capitalization of $3.50 billion, a P/E ratio of -10.49 and a beta of 0.87. The company’s 50-day simple moving average is $31.39 and its two-hundred day simple moving average is $37.20. The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73. Apellis Pharmaceuticals has a 52-week low of $24.34 and a 52-week high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The business had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same quarter in the previous year, the firm posted ($1.17) earnings per share. The company’s revenue was up 78.3% compared to the same quarter last year. Equities research analysts forecast that Apellis Pharmaceuticals will post -1.4 EPS for the current year.

Insider Buying and Selling

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the transaction, the director now owns 100,000 shares in the company, valued at $3,623,000. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 6.80% of the stock is currently owned by insiders.

Institutional Trading of Apellis Pharmaceuticals

Several hedge funds have recently modified their holdings of APLS. KBC Group NV boosted its holdings in shares of Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after buying an additional 679 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at approximately $824,000. Wolverine Asset Management LLC acquired a new position in Apellis Pharmaceuticals in the third quarter worth $27,000. State of New Jersey Common Pension Fund D increased its stake in Apellis Pharmaceuticals by 10.1% during the third quarter. State of New Jersey Common Pension Fund D now owns 49,795 shares of the company’s stock valued at $1,436,000 after purchasing an additional 4,554 shares during the last quarter. Finally, Assetmark Inc. raised its holdings in shares of Apellis Pharmaceuticals by 6.6% during the third quarter. Assetmark Inc. now owns 46,065 shares of the company’s stock worth $1,329,000 after purchasing an additional 2,852 shares during the period. 96.29% of the stock is currently owned by institutional investors and hedge funds.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).